Teclistamab-cqyv

Teclistamab-cqyv (Tecvayli)
Generic Name/API:Teclistamab-cqyv
Packaging:One 30 mg/3 mL (10 mg/ml) and 153 mg/1.7 mL (90 mg/ml) single-dose vial in a carton.
Storage:2°C to 8°C (36°F to 46°F)
Dosage:For dosage information, please check the General Information section.
Strength:Injection 30 mg/3 mL (10 mg/mL) in a single-dose vial 153 mg/1.7 mL (90 mg/mL) in a single-dose viaL
Indication:TECVAYLI is a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager. This innovative immunotherapy works by simultaneously binding to BCMA, a protein found on multiple myeloma cells, and CD3, a protein expressed on the surface of T-cells (a type of immune cell). By bringing these two cells together, TECVAYLI activates the patient's own T-cells to recognize and kill the myeloma cells.

TECVAYLI is a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody. TECVAYLI offers an “off-the-shelf” (readily available) treatment option for heavily pre-treated patients, providing a new avenue for durable responses in a population with limited therapeutic options.

STRENGTH: 

Injection

  •  30 mg/3 mL (10 mg/mL) in a single-dose vial 
  •  153 mg/1.7 mL (90 mg/mL) in a single-dose vial

DOSAGE:  

 TECVAYLI Recommended Dosing Schedule 

Dosing Schedule Day     Dose Step-up Dosing Schedule
Day 1 Step-up dose   1 0.06 mg/kg
Day 4 Step-up dose        2 0.3 mg/kg 
Day 7 First treatment dose 1.5 mg/kg 
Weekly Dosing   One week after first treatment 1.5 mg/kg once
Dose & Weekly Subsequent treatment doses –

ADVERSE  EFFECTS:

  • Vomiting
  • Nervous system disorders 
    • Headache
    • Motor dysfunction
    • Sensory neuropathy
    • Encephalopathy
  • Vascular disorders 
    • Hypotension 
    • Hemorrhage
    • Hypertension
  • Respiratory, thoracic, and mediastinal disorders 
    • Hypoxia 
    • Cough
  • Cardiac disorders
    • Cardiac arrhythmia
  • Metabolism and nutrition disorders 
    • Decreased appetite 
  • Renal and urinary disorders 
    • Acute kidney injury

STORAGE :

2°C to 8°C (36°F to 46°F)

  • Cytokine Release Syndrome: 

TECVAYLI can cause cytokine release syndrome (CRS), including life-threatening or fatal reactions. In the clinical trial, CRS occurred in 72% of patients who received TECVAYLI at the recommended dose, with Grade 1 CRS occurring in 50% of patients, Grade 2 in 21%, and Grade 3 in 0.6%. Recurrent CRS occurred in 33% of patients

  • Neurologic Toxicity including ICANS:

 TECVAYLI can cause serious or life-threatening neurologic toxicity, including Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) In the clinical trial, neurologic toxicity occurred in 57% of patients who received TECVAYLI at the recommended dose, with Grade 3 or 4 neurologic toxicity occurring in 2.4% of patients. The most frequent neurologic toxicities were headache (25%), motor dysfunction (16%), sensory neuropathy (15%), and encephalopathy (13%).

  • Infections: 

TECVAYLI can cause severe, life-threatening, or fatal infections. In patients who received TECVAYLI at the recommended dose in the clinical trial, serious infections, including opportunistic infections, occurred in 30% of patients, with Grade 3 or 4 infections in 35%, and fatal infections in 4.2%

 

Process to Import Medicine

FAQ

TECVAYLI (teclistamab-cqyv) is a bispecific antibody used to treat adult patients with relapsed or refractory multiple myeloma. This means it’s for patients whose cancer has returned or has not responded to previous treatments, specifically those who have received at least four prior lines of therapy, including certain classes of drugs (a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody).

TECVAYLI works as an immunotherapy by acting as a “bridge.” It has two “arms”: one arm binds to a protein called BCMA, which is found on multiple myeloma cells, and the other arm binds to CD3, a protein on your own T-cells (a type of immune cell). By bringing these two cells close together, TECVAYLI activates your T-cells, directing them to recognize and kill the myeloma cells.

Common side effects include Cytokine Release Syndrome (CRS), infections, low blood counts (like low white blood cells, red blood cells, and platelets), fatigue, muscle pain, fever, nausea, and diarrhea.

CRS is a serious side effect that can occur when the immune system becomes overactive, leading to widespread inflammation. Symptoms can include fever, chills, low blood pressure, difficulty breathing, and organ dysfunction. ICANS (Immune Effector Cell-Associated Neurotoxicity Syndrome) is a type of neurologic toxicity that can cause symptoms like confusion, difficulty speaking, headaches, or tremors. Both CRS and ICANS can be serious or life-threatening and require prompt medical attention. Due to the risk, patients receiving TECVAYLI are closely monitored, often requiring hospitalization during the initial step-up dosing.

The cost of tecvayli (teclistamab-cqyv) in India may vary since it is not locally available and usually needs to be imported. Price depends on supplier availability, import duties, and currency fluctuations. For the latest cost details, contact 24/7QualityMeds at +91 9967979080.

To buy tecvayli (teclistamab-cqyv) in India at a genuine price, contact 24/7QualityMeds. We assist patients with the legal import process, ensure authentic supply, and provide safe delivery at the best possible cost.

While selecting a supplier, we essentially ensure that the supplier holds a valid Good Distribution Practice (GDP) certificate and possesses a valid operating license. These credentials confirm that the suppliers adherence to International standards for the proper distribution of medicinal product.

Related products